ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Rhea-AI Summary
ADMA Biologics (Nasdaq: ADMA) will report its fourth quarter and full year 2025 financial results on February 25, 2026 after market close. Management will host a live conference call and audio webcast at 4:30 p.m. ET to discuss results and company updates.
Participants must register to receive dial-in numbers and a unique PIN; a replay will be archived under Events & Webcasts on the company investor website.
Positive
- None.
Negative
- None.
News Market Reaction – ADMA
On the day this news was published, ADMA gained 0.25%, reflecting a mild positive market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $10M to the company's valuation, bringing the market cap to $3.99B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ADMA slipped 0.87% while key biotech peers were mixed to positive (e.g., ACAD up 4.6%, PTGX up 1.71%, MTSR down 0.34%). No peers appeared in the momentum scanner, pointing to a company-specific setup into the earnings date.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Prelim FY2025 update | Positive | -0.1% | Preliminary FY2025 revenue and raised multi‑year guidance with business update. |
| Jan 05 | Conference appearance | Neutral | +0.8% | Announcement of J.P. Morgan Healthcare Conference podium presentation and webcast. |
| Nov 05 | 3Q 2025 earnings | Positive | +5.1% | 3Q 2025 beat with revenue growth, net income, EBITDA expansion and guidance raise. |
| Oct 29 | 3Q earnings date | Neutral | -0.3% | Scheduling of 3Q 2025 earnings release and conference call details. |
Operationally positive news (e.g., strong 3Q 2025 earnings) has previously coincided with notable upside, while guidance and preliminary updates have sometimes seen flat-to-slightly negative reactions.
Over the past several months, ADMA has reported strong fundamentals, including 3Q 2025 revenue of $134.2M, GAAP net income of $36.4M, and raised FY2025–FY2027 revenue and EBITDA targets. A January 2026 update outlined preliminary FY2025 revenue of $510–511M and higher forward guidance, but the stock reaction was muted. Earnings-date announcements like the November 5, 2025 call have historically produced minimal price moves, while full earnings releases have driven more meaningful reactions.
Market Pulse Summary
This announcement schedules ADMA’s fourth quarter and full year 2025 results for February 25, 2026, with a conference call at 4:30 p.m. ET. Recent history shows that detailed earnings releases, such as the strong 3Q 2025 report, have been more impactful than simple timing notices. Ahead of the call, investors may focus on how reported revenue compares with the previously disclosed $510–511M range and whether management updates its multi‑year revenue and adjusted EBITDA targets.
AI-generated analysis. Not financial advice.
Conference Call Scheduled for February 25, 2026, at 4:30 p.m. ET
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report fourth quarter and full year 2025 financial results on February 25, 2026, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.
To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra
INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com
